Technologies
PDF


WARF: P140424US02

Inhibiting Metadherin/SND1 Interaction to Treat Cancer


INVENTORS -

Yongna Xing, Liling Wan, Yibin Kang, Feng Guo

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method to fight tumors using novel peptides that block metadherin and SND1 protein interaction.
OVERVIEWMetadherin (MTDH; also called AEG1 or LYRIC) is a pro-metastasis gene implicated in many types of cancer. The gene is overexpressed in more than 40 percent of primary tumors and is linked to breast cancer relapse and poor prognoses for patients.

What drives this gene and how it plays a role in tumor development remain unclear, but that activity could be a fruitful target for new therapies.
THE INVENTIONUW–Madison researchers and collaborators have developed a method to fight tumor growth and metastasis using novel peptides that inhibit interaction between MTDH and a protein called SND1.

The researchers found that MTDH-SND1 protein interaction is important for the expansion and function of prostate tumors as well as luminal and basal breast tumor initiating cells. Their work provides novel peptides that target this protein complex to help control tumor initiation, recurrence and metastasis by combating tumor initiating cells, with minimal impact on normal tissues.
APPLICATIONS
  • Peptides for oncology therapeutics
  • Possible cancer targets include brain tumors, leukemia, breast cancer, bone and joint cancer, lung cancer, melanoma and prostate cancer.
KEY BENEFITS
  • Potential new weapon against cancer
  • Could help control tumor initiating cells with minimal side effects
  • May be well tolerated in cancer patients
  • Could provide specific, effective therapy to inhibit tumor activity in many cancers
STAGE OF DEVELOPMENTMutated peptides were tested and found to inhibit tumorigenic activity in animal models.
ADDITIONAL INFORMATION
For More Information About the Inventors
Publications
  • Guo F., Wan L., Zheng A., Stanevich V., Wei Y., Satyshur K. A., Shen M., Lee W., Kang Y. and Xing Y. 2014. Structural Insights into the Tumor-Promoting Function of the MTDH-SND1 Complex. Cell Rep. 8, 1704-1713.
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or (608) 265-9861.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.